NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
Clinical Trials
524 trialsNCT05366179 2026-04-22
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT07544992 2026-04-22
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT05917145 2026-04-21
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
Mayo Clinic
Phase 1 Recruiting
NCT07541781 2026-04-21
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
University of Iowa
Phase 1 Not yet recruiting
NCT05557292 2026-04-20
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
University of California, San Francisco
Phase 1 Terminated
NCT02287428 2026-04-17
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05698524 2026-04-17
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT03451799 2026-04-15
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Completed
NCT06641908 2026-04-15
Anti-GD2 ADC M3554 in Advanced Solid Tumors
EMD Serono
Phase 1 Recruiting
NCT00268385 2026-04-13
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT03911388 2026-04-13
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05168423 2026-04-13
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
University of Pennsylvania
Phase 1 Active not recruiting
NCT06860594 2026-04-13
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Suspended
NCT07422363 2026-04-13
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT06344130 2026-04-09
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07134842 2026-04-09
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT04978727 2026-04-06
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Phase 1 Active not recruiting
NCT07497373 2026-04-03
JL15003
Jecho Biopharmaceuticals Co., Ltd.
Phase 1 Completed
NCT05789394 2026-04-02
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
Phase 1 Recruiting
NCT06650605 2026-03-31
CITADEL-123
Ariceum Therapeutics GmbH
Phase 1 Completed
NCT04197934 2026-03-30
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
Phase 1 Active not recruiting
NCT06934889 2026-03-30
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04019002 2026-03-27
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
University of California, San Francisco
Phase 1 Completed
NCT05139056 2026-03-27
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Suspended
NCT05303467 2026-03-27
FRONTIER
Boston Scientific Corporation
Phase 1 Recruiting
NCT05283330 2026-03-20
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Phase 1 Recruiting
NCT07464925 2026-03-20
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Phase 1 Not yet recruiting
NCT04573140 2026-03-19
PNOC020
University of Florida
Phase 1 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT04678648 2026-03-18
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
Phase 1 Recruiting
NCT07480941 2026-03-18
DUAL-CAR-NK-GB
Beijing Biotech
Phase 1 Recruiting
NCT04732065 2026-03-17
PNOC023
University of California, San Francisco
Phase 1 Recruiting
NCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT06186401 2026-03-16
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
University of California, San Francisco
Phase 1 Recruiting
NCT03749187 2026-03-13
PNOC017
University of California, San Francisco
Phase 1 Active not recruiting
NCT06946680 2026-03-13
IMPACT
University of Florida
Phase 1 Active not recruiting
NCT05743595 2026-03-11
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT04716699 2026-03-10
Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma
University of California, Davis
Phase 1 Completed
NCT05353530 2026-03-09
IMPACT
University of Florida
Phase 1 Active not recruiting
NCT06389591 2026-03-09
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
University of Florida
Phase 1 Active not recruiting
NCT07455045 2026-03-06
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT03896568 2026-03-05
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04661384 2026-03-05
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06917885 2026-03-05
CUE-102 in Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03152318 2026-03-04
rQNestin
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT06665724 2026-02-27
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
Phase 1 Completed
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT03389802 2026-02-20
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Phase 1 Active not recruiting